Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (11533)	11/20/1997 1:57:00 PM
From: Proton	Read Replies (1) \| Respond to of 32384

Re: AMLN, NVO, LGND They are selling more AMLN because even more competition First, thanks for the article, it is a nice supplement to a particular poster's links on the subject from earlier today. :-) Second, doesn't a Type II diabetes therapy provide competition to LGND, as well? Is your statement about relative competition based on LGND's overall pipeline? My layman's understanding is this: after a quite severe drought in new therapies, several diabetes treatments have come to the approval window for 1997-1998. What will distinguish LGND's offering, especially if effective agents hit the market sooner? What will get investor's attention? Besides revenues, of course... Pý